Serum Sclerostin and Adverse Outcomes in Nondialyzed Chronic Kidney Disease Patients

Abstract

This is the first study that shows that serum sclerostin values are associated, even after multiple adjustments, with fatal and nonfatal CVEs in a nondialyzed CKD population.